Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01582750
Recruitment Status : Unknown
Verified September 2013 by Jing Jin, M.D., Chinese Academy of Medical Sciences. Recruitment status was: Recruiting
First Posted : April 23, 2012
Last Update Posted : September 19, 2013
Chinese Academy of Medical Sciences
Information provided by (Responsible Party):
Jing Jin, M.D., Chinese Academy of Medical Sciences
The purpose of this study is to determine the role of endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values in predicting the tumor regression after concurrent chemoradiotherapy for rectal cancer.
Condition or disease
We use endoscopic ultrasound to measure the primary tumor maximum diameter changes to predict the tumor regression after concurrent chemoradiotherapy for rectal cancer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Local advanced rectal cancer
pathologically confirmed rectal cancer, preoperative stage II / III (T3-4N0 or T1-4N + M0).
tumor distance from anus less than 12 cm.
KPS score not less than 70
can be tolerated chemotherapy and radiotherapy.
pelvic who had no history of radiation therapy.
Non-allergic history of fluorouracil or platinum-based chemotherapy drugs.
a full understanding of the study, the ability to complete all of the treatment plan, follow up the conditions and sign the informed consent.
other malignancy (past or at the same time), does not include curable non-melanoma skin cancer and cervical carcinoma in situ; does not include resectable primary colon cancer (synchronous or metachronous).
pregnant or lactating patients.
fertility but did not use contraceptive measures.
existing active infection.
merge serious complications, can not tolerate the treatment, such as 6 months of myocardial infarction, mental illness, uncontrollable diabetes or uncontrollable hypertension or hypotension.